The aim of this study was to evaluate and compare the diagnostic value of CD56, SMAD4, CEA, and p53 biomarkers in diagnosing cholangiocarcinoma and its benign mimickers. This evidence concerns the gene NCAM1 and cholangiocarcinoma.